Pseudoexfoliation Syndrome and Antidepressant Drug Use

Erdoğan Yaşar*, Nilgün Yıldırım**, Eray Atalay**

*Aksaray University Training and Research Hospital, Ophthalmology Clinic, Aksaray, Turkey
**Eskişehir Osmangazi University Faculty of Medicine, Department of Ophthalmology, Eskişehir, Turkey

Abstract

Objective: To investigate the relationship between pseudoexfoliation syndrome (PES) and the use of antidepressant medications.

Materials and Methods: This population-based, cross-sectional study included 2,017 of 2,356 invited subjects who were randomly selected from the Turkish Statistical Institute database (www.turksat.gov.tr/) as part of an epidemiologic study which specifically aimed to detect the prevalence of PES in the province of Eskişehir. During the examination, a detailed questionnaire was administered to determine physician-diagnosed systemic disease and drug use.

Results: Eight of the 2,017 participants in the study were excluded for various reasons (2 with posterior synechiae, 2 with corneal opacity, 1 uncooperative patient, 1 eviscerated patient, 1 with active adenoviral keratoconjunctivitis, and 1 with a history of angle closure). PES was detected in 100 (5%) of the 2,009 patients whose data were analyzed. The percentage of subjects with concurrent antidepressant drug use in the PES and non-PES non-glaucoma groups were 4.1% (n=3) and 1.1% (n=21), respectively. The difference between the two groups was statistically significant (p=0.024). In addition, the use of medications for hypertension (p<0.001) and coronary artery disease (p=0.009) was also higher in the PES group.

Conclusion: The higher prevalence of antidepressant drug use in patients with PES may be related to the processes of vascular damage and inflammation common to the pathogenesis of both PES and depression, as well as the high rate of chronic systemic comorbidities in these patients.

Keywords: Pseudoexfoliation, depression, antidepressant drug

Introduction

Pseudoexfoliation syndrome (PES), first described by Lindberg in 1917, is a clinical entity characterized by the accumulation of gray-white extracellular fibrillary material in the anterior segment tissues of the eye.1,2 Besides the eye, exfoliative material (EM) has also been detected in the heart, lung, liver, kidney, and meninges using light/electron microscopy and immunohistochemical/biochemical methods.3,4

Oxidative damage and inflammation caused by free radicals has been shown to have a role in the pathogenesis of PES.5,6,7 Increased oxidative stress and subsequent impairment of cellular immunity through the proteasome system are believed to be instrumental in the pathogenesis of PES.1 Electron microscope studies of iris tissue samples from patients with PES have demonstrated EM deposition and damage to the iris vessels.8,9 Furthermore, histopathological examination of samples obtained from PES patients with aortic aneurysm revealed focal accumulation of EM, pronounced fibrosis, and tunica intima elastosis in the adventitial and subendothelial connective tissue.10 A recent genetic study identified five novel loci associated with predisposition for PES and the risk ratio for one of these loci varied by geographical latitude (increasing toward the polar regions).11
PES is a clinical condition that increases in frequency in individuals over the age 50 and with increasing age. Various studies have shown that the incidence and prevalence of PES varies in different populations, even within the same population in different regions, and its frequency varies between 0% and 38%. In addition to secondary glaucoma, cataract, and complications related to cataract surgery, PES patients have higher rates of hypertension (HT), coronary artery disease (CAD), heart attack, stroke, Alzheimer’s disease, peripheral vascular diseases, and hearing loss, illustrating the systemic character of PES. In a study comparing patients with pseudoexfoliation glaucoma (PXG), primary open-angle glaucoma (POAG), and a control group showed that depression was significantly more common in the pseudoexfoliative group while the POAG and control groups had similar rates of depression, suggesting that PES may be associated with depression. The aim of this study was to investigate the relationship between PES and depression and other systemic diseases based on survey results from our population-based cross-sectional PES prevalence study.

Materials and Methods

The study was carried out in accordance with the principles of the Declaration of Helsinki and ethical approval was obtained from the Ethics Committee of Eskişehir Osmangazi University (7 February 2013, project number: 06). This population-based randomized study was part of an epidemiological study to determine the prevalence of PES in Eskişehir, Turkey, a city covering 2,678 km² with a population of 826,716. Randomization was done with a centralized method using the Turkish Statistical Institute database. This database contains regularly updated address information for all residents of Eskişehir. The target population consisted of people aged 40 and over living in the urban center and rural areas of Eskişehir.

A layered two-stage cluster sampling method was used for randomization and the study was conducted between 15 June and 1 October 2014 using the most recent information from February 2014. In the first sampling phase, clusters of approximately 100 households were probability sampled in proportion to their size. In the second phase, 10 households were randomly selected from each cluster using systemic sampling. Residence data for the selected households were obtained from local archives. People aged 40 years and over who resided in the randomly selected households were contacted through the neighborhood representative and invited to participate. The 100 people with PES were evaluated by the glaucoma consultant for confirmation (N.Y.).

Statistical Analysis

All statistical analyses were performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL). A t-test was used to compare numerical variables and chi-square test was used to compare the distribution of categorical variables between groups. Statistical significance was accepted as p<0.05.

Results

Of the 2,356 people who were randomly selected and invited to the study, 2,017 (85.6%) participated. Eight of the 2,017 participants (2 with posterior synechiae, 2 with corneal opacities, and 4 who were uncooperative, had one eviscerated eye, had adenoovarial conjunctivitis, or had history of narrow-angle glaucoma) were excluded from the analysis. Demographic characteristics of the individuals with and without PES who were included in the study are summarized in Table 1. PES was detected in 100 (5%) of the 2,009 participants. The mean age of the 100 people with PES was 69.1±9.9 years and that of the individuals without PES was 59.2±10.9 years (p<0.001).

After 33 glaucoma patients were excluded from 1,909 non-PES subjects, antidepressant drug use was reported by 21 (1.1%) of the remaining 1,876 subjects (mean IOP: 14.7±3.4 mmHg). After 26 glaucoma patients were excluded from 100 subjects with PES, antidepressant drug use was reported by 3 (4.1%) of the remaining 26 subjects (mean IOP: 14.1±3.3 mmHg). There was no statistical difference in mean IOP between the groups, whereas the incidence of antidepressant use was significantly higher in patients with PES (p=0.024, Table 2). Details regarding the physician-prescribed antidepressant drugs are shown in Table 3.
In addition, the results of the survey questions regarding physician-diagnosed disease and drug use revealed that of the 1,909 non-PES subjects, 626 (32.8%) used antihypertensive drugs and 162 (8.5%) used medication for CAD. These rates were significantly higher in the 100 subjects with PES, with 48% using antihypertensive drugs ($p<0.001$) and 17% taking medication for CAD ($p=0.009$). No significant difference was found between the groups in terms of drugs used for other diseases ($p>0.05$) (Table 4).

Discussion

In our study, PES was detected in 100 of 2,009 individuals evaluated (5%). Other studies of PES prevalence in the Turkish population reported rates in the 7-12% range, higher compared to our population-based randomized study.23,24,25,26 This may be explained by the fact that those studies were hospital-based.

Antidepressant drug use was identified in 21 (1.1%) of 1,876 people without PES or glaucoma and in 3 (4.1%) of 74 patients with PES but without glaucoma, which was a statistically significant difference ($p=0.024$).

There is only one study in the literature showing an association between PES and depression, and it was conducted in patients with PXG. Cumurcu et al.21 evaluated the prevalence of depression in 41 PXG patients, 32 POAG patients, and 40 control groups. Based on findings from other researchers indicating that depression was common in chronic disease and reasoning that glaucoma was a chronic disease, they expected depression rates to be higher in both PXG and POAG patients; however, only the PXG group showed a significantly higher prevalence of depression compared to the control group.27 The higher prevalence of depression in the PXG group suggested that the vascular damage involved in the pathogenesis of depression might be associated with pseudoexfoliation, supporting the vascular depression hypothesis.27,28 Unlike the study by Cumurcu et al.,21 we excluded patients with glaucoma to include subjects with PES only. Numerous studies have shown that depression is more common in patients with CAD, diabetes, and HT.29,30 Of the 6 participants with PES and psychiatric disease identified in our study, 4 had concomitant diabetes, HT, or CAD; considering the vascular etiology of depression, this may have increased antidepressant use in these patients. The presence of multiple chronic comorbidities may have led to depression in these individuals.

Oxidative damage and inflammation caused by free radicals was shown to have a role in the pathogenesis of PES.3,6,7 Various studies have also reported that oxidative stress and inflammation may be involved in the pathogenesis of depression.31,32 Inflammation induced by the accumulation of pseudoexfoliative material in the brain may trigger depression and increase antidepressant drug use in PES patients.

Moreover, ischemic heart disease, history of angioplasty, HT, and hearing loss were more common in the PES group than in controls. The higher prevalence of other diseases, even if not statistically significant, may be a factor contributing to antidepressant drug use. Loss of health and the limitations imposed by chronic diseases cause the higher incidence of depression with these diseases.33 Various studies have shown that

---

### Table 1. Age and sex distribution of participants with and without pseudoexfoliation syndrome

|               | n % | Mean age (years) sex | Mean age (years) general |
|---------------|-----|----------------------|-------------------------|
| Female        | 53  | 67.3±10.7            |                         |
| PES (+) (n=100) | 47  | 71.1±8.7             | 69.1±9.9                |
| Male          | 47  | 53.7                 | 59.2±10.9               |
| PES (-) (n=1909) | 884 | 60.9±11.0            |                         |
| PES: Pseudoexfoliation syndrome |

### Table 2. Comparison of antidepressant use in participants with and without pseudoexfoliation syndrome

|               | PES (+), n (%) | PES (-), n (%) | p  |
|---------------|----------------|----------------|----|
| Antidepressant drug use | 3 (4.1)        | 21 (1.1)       | 0.024 |

### Table 3. The distribution of participants with and without pseudoexfoliation syndrome diagnosed with depression and using antidepressant drugs

| SSRI          | PES (+), n (%) | PES (-), n (%) |
|---------------|----------------|----------------|
| Escitalopram  | 2              | 9              |
| Citalopram    | -              | 1              |
| Sertraline    | 1              | 6              |
| Paroxetine    | -              | 1              |
| Venlafaxine   | 1              | 5              |

SSRI: Selective serotonin reuptake inhibitor, SNRI: Serotonin-norepinephrine reuptake inhibitor

### Table 4. Comparison of systemic drug use in participants with and without pseudoexfoliation syndrome

| Drug class                           | PES (+), n (%) | PES (-), n (%) | p  |
|--------------------------------------|----------------|----------------|----|
| Antihypertensive drug                | 48 (48)        | 626 (32.8)     | 0.001 |
| Cardiac drug                         | 22 (22)        | 210 (11.0)     | 0.001 |
| Antidiabetic drug                    | 25 (25)        | 483 (25.3)     | 0.05  |
| Hypercholesterolemia drug            | 3 (3)          | 57 (3.0)       | 0.05  |
| Neurologic drug                      | 8 (8)          | 92 (6.1)       | 0.05  |
| Antithyroid drug                     | 7 (7)          | 120 (6.3)      | 0.05  |
| Antirheumatic drug                   | 2 (2)          | 37 (1.9)       | 0.05  |
| Asthma/COPD medication               | 6 (6)          | 69 (3.6)       | 0.05  |
| Gastrointestinal disease medication  | 6 (6)          | 41 (2.7)       | 0.05  |
| Osteoporosis medication              | 2 (2)          | 28 (1.5)       | 0.05  |
| Prostate disease medication          | 2 (2)          | 32 (1.7)       | 0.05  |

PES: Pseudoexfoliation syndrome, COPD: Chronic obstructive pulmonary disease
depression is more common in patients with CAD, diabetes, asthma, and cancer.33,35,36,37

Of the 100 PES patients in our study, 48% had HT and 17% had ischemic heart disease; consistent with the literature, these rates were significantly higher when compared with patients without PES (p<0.001). Previous studies have demonstrated the relationship between PES and systemic diseases such as HT, CAD, heart attack, peripheral vascular diseases, ischemic brain diseases, stroke, and Alzheimer’s disease.4,15,16,17,18,19,20 In a recent study, 62% of 260 patients who presented for cataract surgery had cardiovascular diseases, 46.5% with HT and 19.7% with ischemic heart disease.38 Furthermore, a significant relationship has been reported between PES and sensorineural hearing loss.39,40

Study Limitations

Limitations of our study are that we did not perform brain imaging in PES patients using antidepressant drugs to rule out a central etiology of depression, and we did not evaluate for family history of depression.

Conclusion

The higher prevalence of antidepressant drug use among patients with PES illustrates the need for further research to determine the relationship between PES and depression.

Ethics

Ethics Committee Approval: Eskişehir Osmangazi University (7 February 2013, decision no: 06).
Informed Consent: Informed consent was obtained.
Peer-review: Externally peer-reviewed.

Authorship Contributions
Concept: Nilgün Yıldırım, Design: Eray Atalay, Data Collection or Processing: Erdoğan Yaşar, Analysis or Interpretation: Nilgün Yıldırım, Literature Search: Erdoğan Yaşar, Writing: Erdoğan Yaşar, Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The authors declared that this study received no financial support.

References

1. Yıldırım N. Pseudoeksofolasiyon glokomunda moleküler patofizyoloji. Türkiye Klinikleri J Ophthalmol-Special Topics. 2012;5:24-29.
2. Schlötz-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol. 1992;110:1752-1756.
3. Streeter BW, Li ZY, Wallace RN, Eagle RC Jr, Keshgegian AA. Pseudoexfoliative fibrilopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch ophthalmol. 1992;110:1757-1762.
4. Naumann GO, Schlötz-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifestations. Ophthalmology. 1998;105:951-968.
5. Schlötz-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
6. Moreno-Montanes J, Lajara Blesa J. IgG, albumin and total IgG index in the aqueous humour of eyes with pseudoexfoliation syndrome. Acta Ophthalmol Scand. 1995;73:249-251.
7. Berlau J, Lorenz P, Beck R, Makovitzky J, Schlötz-Schrehardt U, Thiesen HJ, Guthoff R. Analysis of aqueous humour proteins of eyes with and without pseudoexfoliation syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239:745-746.
8. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol. 1997;124:685-687.
9. Shimizu T. Changes of iris vessels in capsular glaucoma: three dimensional and electron microscopic studies. Jpn J Ophthalmol. 1985;29:454-452.
10. Schumacher S, Schlötz-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359-360.
11. Aung T, Ozaki M, Lee MC, Schlötz-Schrehardt U, Theelseison G, Mazouzguicha T, Igo RP Jr, Harzipria A, Williams SE, Astakhow YS, Orr AC, Burdon KP, Nakano S, Mori K, Abu-Amuro K, Hauser M, Li Z, Prakadeswarai G, Bulay JNC, Cherecheau AP, Kang JH, Nelson S, Hayashi K, Manabe SI, Kacarina N, Zarnowsk T, Inoue K, Irmec M, Coca-Prados M, Sugiyama K, Jarvela I, Schlottmann P, Lerm S, Lambropoulos A, Gheso A, Shetty R, Porporato V, Saravanavan V, Venkatesh R, Shikumaru C, Kalpana N, Sarangapani S, Kanavi MR, Beni AN, Yazdiani S, Lashay A, Naderifar H, Khatifar N, Pea A, Lavia C, Dallorto L, Rolle T, Freztori E, Paoli D, Salvi E, Manunta P, Mori Y, Miyata K, Higashi T, Chihara E, Ishioka S, Yoshihara A, Yamagi M, Kuchiyi Y, Ohashi T, Sakurai T, Sugimoto T, Chuman H, Aliara M, Inatara M, Miyako M, Gotokh N, Matsuda F, Yoshiumara N, Ikeda Y, Ueno M, Sorotana C, Joosung JW, Sagon M, Park KH, Ahn J, Cruz-Aguilar M, Ezosahaim SM, Rafa A, Chong YE, Ng XY, Goh SR, Chen Y, Yong VH, Khan M, Olawowe AO, Ashaye AO, Ugbedie I, Onakoya A, Kizor-Akaaiwa N, Terekhasaanara C, Sunwan S, Supakontanasan W, Okete S, Uche NJ, Asimud A, Iyubh A, Hcktar F, Kosuxor-Jarecka E, Lukasus U, Lusinchiy I, Castor V, Grossmann RP, Sunaric Megevand G, Roy S, Dervan E, Silke E, Rao A, Sahay P, Fornero P, Cuello O, Siveri D, Zompa T, Mills RA, Souzeau E, Mitchell F, Wang JJ, Hewett AW, Coote M, Bowerton JG, Astakhow SY, Akopov EL, Emeljyanov A, Voschinsyavka V, Kazhakbaeva G, Fayzakhmanov R, Al-Obaidan SA, Owaishah O, Alajbian LA, Chowbay B, Foo JN, Sol RH, Sim KS, Xie Z, Cheong AWO, Mak SQ, Soo HM, Chen XY, Peh SQ, Heng KH, Huain RN, Ho SL, Millar AM, Cheng CY, Escudero-Dominguez FA, Gonzalez-Sarmiento R, Martinon-Torres F, Salas A, Pathanapoison K, Hansapinno Y, Wanicharanghaungthi B, Kinraorong N, Sakuntabhai A, Nguyen HX, Nguyen GTT, Nguyen TV, Zenn W, Binder A, Kloobasa DS, Hibblel MI, Davila S, Herms S, Nøttien MM, Morbus S, Rautenbach RM, Zikond A, Carmichael TR, Ramsay M, Alvarez L, García M, González-Iglesias H, Rodriguez-Calvo PF, Fernández-Vega Cuto L, Oguz Ç, Tamekic N, Atalay A, Baet B, Aksul A, Kvaal B, Wilson MR, Coleman AL, Liu Y, Challa P, Herdson L, Kuchyte R, Kuchyte J, Curtin K, Chaya CJ, Cadrajal A, Zaggwil LWM, Wong TY, Nakano M, Kinohita S, de Hollandan AI, Vieti E, Fingert JH, Lee RK, Stir A, Shingleon BJ, Wang N, Cusi D, Qamr K, Raff M, Pericak-Vance MA, Raychaudhurin SA, Hegodda S, Viebó T, Reis A, Kruse FE, Weinho RN, Pasque LHR, Haines J, Threstlesinditor U, Jonasson F, Allingham RR, Miles D, Rich R, Kubota T, Tashiro K, Virhana EK, Micheal S, Topouzis F, Craig JE, Dubina M, Sundaresan P, Stefanos K, Wiggins J, Khoe CC. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. Nat Genet. 2017;49:999-1004.
alterations of the cornea and conjunctiva. Acta Ophthalmol Scan. 2002;80:478-484.

13. Kozobolis VP, Papatzanakis M, Vlachonikolis IG, Pallikaris IG, Tsambarakis IG. Epidemiology of pseudoexfoliation in the island of Crete (Greece). Acta Ophthalmol Scand. 1997;75:726-729.

14. Cahill M, Early A, Stack S, Blayney AW, Eustace P. Pseudoexfoliation and sensorineural hearing loss. Eye (Lond). 2002;16:261-266.

15. Jonas JB, Nangia V, Matrin A, Bhoywani K, Sinha A, Khare A, Agarwal S, Bhat K. Pseudoexfoliation: normative data and associations. The Central India Eye and Medical Study. PloS One. 2013;8:76770.

16. Akarsu C, Uzal B. Cerebral haemodynamics in patients with pseudoexfoliation glaucoma. Eye (Lond). 2005;19:1297-1300.

17. Uysal T, Nadir A, Yaz YA, Ozdemir AO, Murlu E, Yazici HU, Cavusoglu Y, Yildirim N. Cardiovascular involvement in patients with pseudoexfoliation syndrome. J Cardiovasc Med (Hagerstown) 2013;14:587-592.

18. Kovac B, Vukosavljevic M, Janicijevic MP, Resan M, Jankovic J. The prevalence of pseudoexfoliation syndrome and possible systemic associations in patients scheduled for cataract surgery at the Military Medical Academy in Belgrade. Vojnosanitetski Pregl. 2014;71:839-844.

19. Schumacher S, Schlöter-Schrehardt U, Marxus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2000;357:359-360.

20. Janciauskiene S, Krakau T. Alzheimer’s peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome. Doc Ophthalmol. 2003;106:215-223.

21. Cumurcu T, Cumurcu BE, Celikel FC, Ertikan I. Depression and anxiety in patients with pseudoexfoliative glaucoma. Gen Hosp Psychiatry. 2006;28:509-515.

22. Yildirim N, Yasar E, Gursoy H, Colak E. Prevalence of pseudoexfoliation syndrome and its association with ocular and systemic disease in Eskisehir, Turkey. Int J Ophthalmol. 2017;10:128-134.

23. Yalaz M, Othman I, Nas K, Ergulu A, Hornuru D, Cikintas Z, Ashoury A. The frequency of pseudoexfoliation syndrome in the eastern Mediterranean area of Turkey. Acta Ophthalmol (Copenhagen). 1992;70:209-213.

24. Halay H, Ensor G. Pseudoexfoliation syndromu (istenistrikstil bir çalışma). Turk J Ophthalmol. 1989;19:63-66.

25. Cumurcu T, Kilic R, Yologlu S. The frequency of pseudoexfoliation syndrome in the middele Black Sea region of Turkey. Eur J Ophthalmol. 2010;20:1007-1011.

26. Gunus A, Yasar C, Tok L, Tok O. Prevalence of pseudoexfoliation syndrome in Turkish patients with senile cataract. Semin Ophthalmol. 2017;32:297-301.

27. Thomas AJ, Kalatia RN, T O'Brien JT. Depression and vascular disease: what is the relationship? J Affect Disord. 2004;79:81-95.

28. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Carlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54:915-922.

29. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.

30. Edb C, Barza A, Lietz A, Bayer AL, Flammer J, Thiel HJ. Psychological characteristics of patients with normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1999;237:753-757.

31. Reason CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.

32. Elmi H. Kronik hastalik ve depresyon. J Clin Psy. 2008;11:3-18.

33. Hayward C. Psychiatric illness and cardiovascular disease risk. Epidem Rev. 1995;17:129-138.

34. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069-1078.

35. Mancuso CA, Peterson MG, Carlson ME. Effects of depressive symptoms on health-related quality of life in asthma patients. J Gen Intern Med. 2000;15:301-310.

36. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, Gershenson DM. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78:302-308.

37. Tijani M, Albaroudi N, Burstmunze N, Cherkaoui O, Laghmari M. Prevalence of exfoliation syndrome and cardiovascular diseases in patients scheduled for cataract surgery. J Fr Ophtalmol. 2017;40:623-628.

38. Shazly TA, Farrag AN, Karmel A, Al-Hussaini AK. Prevalence of pseudoexfoliation syndrome and pseudoxfoliation glaucoma in upper Egypt. BMC Ophthalmol. 2011;11:18.

39. Turaci ME, Ozlemir FA, Tekeli O, Gökcan K, Gerekier M, Dürük K. Sensorineural hearing loss in pseudoexfoliation. Can J Ophthalmol. 2007;42:56-59.